Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)

F Morschhauser; D Huglo; G Martinelli; G Paganelli; P Zinzani; D Hadjiyiannakis; A Liberati; T Illidge; N Milpied; J Kalmus; P Morel; U Reimann; R Marcus

Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)

F Morschhauser, D Huglo, G Martinelli, G Paganelli, P Zinzani, D Hadjiyiannakis, A Liberati, T Illidge, N Milpied, J Kalmus, P Morel, U Reimann, R Marcus

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	54
Number of pages	1
Journal	Annals of Oncology
Volume	16
Issue number	Suppl. 5
Publication status	Published - Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Morschhauser, F., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P., Hadjiyiannakis, D., Liberati, A., Illidge, T., Milpied, N., Kalmus, J., Morel, P., Reimann, U., & Marcus, R. (2005). Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL). Annals of Oncology, 16(Suppl. 5), 54.

@article{2dcc3028b5204a08973a5fc83e070e29,

title = "Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)",

author = "F Morschhauser and D Huglo and G Martinelli and G Paganelli and P Zinzani and D Hadjiyiannakis and A Liberati and T Illidge and N Milpied and J Kalmus and P Morel and U Reimann and R Marcus",

year = "2005",

month = jun,

language = "English",

volume = "16",

pages = "54",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "Suppl. 5",

}

Morschhauser, F, Huglo, D, Martinelli, G, Paganelli, G, Zinzani, P, Hadjiyiannakis, D, Liberati, A, Illidge, T, Milpied, N, Kalmus, J, Morel, P, Reimann, U & Marcus, R 2005, 'Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)', Annals of Oncology, vol. 16, no. Suppl. 5, pp. 54.

TY - JOUR

T1 - Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)

AU - Morschhauser, F

AU - Huglo, D

AU - Martinelli, G

AU - Paganelli, G

AU - Zinzani, P

AU - Hadjiyiannakis, D

AU - Liberati, A

AU - Illidge, T

AU - Milpied, N

AU - Kalmus, J

AU - Morel, P

AU - Reimann, U

AU - Marcus, R

PY - 2005/6

Y1 - 2005/6

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233670100066&KeyUID=WOS:000233670100066

M3 - Meeting Abstract

SN - 0923-7534

VL - 16

SP - 54

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 5

ER -

Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)

UN SDGs

Other files and links

Cite this